Biogen, Inc. has listed driving a potential return to growth in its biosimilars business as one of its key near-term operational priorities, after its biosimilars revenue decreased 5% year-on-year during the first quarter of 2022. Pricing pressure and negative currency impacts took their toll on the segment, as revenue decreased from $205m in Q1 2021 to $194m this year, with the company ultimately expecting a “slight” decline in full-year biosimilars revenue overall compared to 2021.
The firm currently has three biosimilars on the market: Imraldi (adalimumab), Flixabi (infliximab) and Benepali (etanercept), developed through the
